Director Li Nan purchases 1.1M shares for $20M and converts 1.7M in restricted stock on same day
Li Nan, a director of Odyssey Therapeutics, combined a substantial open-market purchase of 1.1 million shares at $18 with a conversion of restricted stock on the same date, accumulating 2.8 million shares in total. This represents the director's first open-market purchase on record in our data window, marking a significant entrance into direct ownership. The timing is noteworthy: the current stock price sits above the available 52-week reference point, yet the director elected to commit approximately $20 million to the position. With no prior open-market purchases or sales in the filing history, this inaugural trade demonstrates a material commitment to ownership rather than a gradual or opportunistic entry pattern. The combination of a large open-market buy alongside a restricted-stock conversion suggests coordination between incentive-based and discretionary capital deployment.